Bayer for ProfessionalsYour Resource Portal

Resources

mCRC Resources

Here you will find relevant materials related to Stivarga® (regorafenib) in mCRC, as well as links to relevant articles and publications.

Stivarga as a targeted alternative after cytotoxic chemotherapy in mCRC

Download PDF

Proven efficacy in mCRC across clinical trials and real-world evidence

Download PDF

Stivarga Prescribing Information

mCRC Guidelines

Stivarga Prescribing Information

PP-STI-GB-0206, February 2024

Stivarga® (regorafenib)

In mCRC

Stivarga Prescribing Information

PP-STI-GB-0204, February 2024

Tyrosine Kinase Inhibitors (TKI) Events & Webinars

PP-PF-ONC-GB-0412, February 2024

PP-STI-GB-0199 | February 2024

Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.

Further information is available on the "contact" tab at www.bayer.co.uk.